Drug Approval | June 12, 2022
China NMPA approves Tislelizumab for metastatic nasopharyngeal cancer
Tislelizumab is now approved in nine indications in China
Tislelizumab is now approved in nine indications in China
New Director supports NASDAQ rule on diversity
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
The company has posted net profit of Rs.39.71 crores for the Financial Year ended March 31, 2022.
CerTest Biotec uses the BD MAX molecular diagnostic system open system reagent suite to develop RT-PCR detection kit
Active pharmaceutical ingredients revenue for the quarter was at Rs 913 crore
New Regional Processing Lab will serve Ahmedabad and the state of Gujarat
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
Norliqva was approved by the FDA on February 24, 2022 and is now available through normal retail distribution.
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
Subscribe To Our Newsletter & Stay Updated
